The Mima patients
Facts and figures about our patient community.
The Mima patient community was established and grew around Solid Tumours. It is now expanding into Malignant Haematology conditions.
(All figures are actual as of 15th October 2025, and will be updated regularly to reflect the growth and evolution of our community)
Note: Definitions may vary by type of cancer; in most cases, early vs advanced refers to non-metastatic vs metastatic disease.
Strong in high-unmet-need cancers
Solid tumours – by cancer type
| Cancer Type | Patients | Percentage | Distribution |
|---|---|---|---|
| Breast | 2,880 | 36% | |
| Lung | 1,280 | 16% | |
| Colon | 1,120 | 14% | |
| Prostate | 640 | 8% | |
| Ovarian | 460 | 5% | |
| Other (50+ types) | 1,680 | 21% |
Hematological cancers
Blood cancers – expanding coverage
| Cancer Type | Patients | Percentage | Distribution |
|---|---|---|---|
| Lymphomas | 441 | 45.37% | |
| Leukemias | 342 | 35.19% | |
| Myelomas | 159 | 16.36% | |
| Myeloid Disorders (MDS/MPN) | 30 | 3.09% |
Total hematological cancer patients: 972
Across disease stages
Early and advanced stage distribution
By geography
Multi-region patient coverage
| Region | Patients | Percentage | Distribution |
|---|---|---|---|
| Europe | 2,800 | 35% | |
| Americas | 2,000 | 25% | |
| North Africa | 2,000 | 25% | |
| Other | 1,200 | 15% |
Engagement and richness of data
Highly engaged community with rich longitudinal data
Well profiled / rich metadata
Highly engaged
These numbers illustrate the value and depth of the Mima patient community for research. Our engaged, well-profiled patients across multiple cancer types and geographies provide a strong foundation for rigorous, patient-centred studies.
Learn how we collaborate with partners